Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 for Quarter ended June 30, 2016
Ortin Laboratories Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended June 30, 2016, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Shareholding for the Period Ended June 30, 2016
Ortin Laboratories Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2016. For more details, kindly Click here Declaration regarding Audit Report with unmodified opinion.
Ortin Laboratories Ltd has submitted to BSE a copy of Declaration regarding Audit Report with unmodified opinion. Standalone Financial Results, Auditors Report for March 31, 2016
Ortin Laboratories Ltd has informed BSE about : 1. Standalone Financial Results for the period ended March 31, 20162. Standalone Auditors Report for the period ended March 31, 2016 Closure of Trading Window
Ortin Laboratories Ltd has informed BSE that the trading window in respect of the Companys Securities shall remain closed for all the Directors/Officers/Designed Employees of the Company from the trading hours on May 17, 2016 till close of the trading hours on June 01, 2016 as per the code of Internal Procedure and Conduct for Prevention of Insider Trading adopted by the Company for declaration of audited financial results for the quarter and year ended March 31, 2016. Board Meeting on May 30, 2016
Ortin Laboratories Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on May 30, 2016, inter alia, to consider the following:1. Audited financial results for the quarter and year ended March 31, 2016.2. Audit Report for the Quarter and Year ended March 31, 2016.3. Appointment of Secretarial auditor for the year 2016-17. Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 for Quarter ended March 31, 2016
Ortin Laboratories Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended March 31, 2016, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Shareholding for the Period Ended March 31, 2016
Ortin Laboratories Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2016. For more details, kindly Click here Outcome of Board Meeting
Ortin Laboratories Ltd has informed BSE that the Board of Directors of the Company at its meeting held on February 11, 2016, inter alia, has considered and approved the following:1. Appointment of secretarial auditor for the financial year 2015-16.2. The Board has considered the proposal and decided to start OTC Marketing of Products like Cough Syrup, Pain cream, Pain Spray, Pain tablets, Anti Cold tablets all over India which will yield good revenue in coming years....